Ipsos highlights “longevity shift” redefining physician engagement and healthcare communication
Ipsos explores how longevity medicine is reshaping physician engagement and its implications for healthcare media strategies
A new point of view from Ipsos outlines how the rise of longevity medicine is reshaping physician engagement models- signalling potential implications for how pharma and healthcare brands approach media and communication strategies.
The report, “The Longevity Shift: A New Era of Physician Engagement in Longevity Medicine,” explores how a growing cohort of “wellness-driven” patients is changing the dynamics of clinical interactions. These patients increasingly arrive armed with wearable data, biological age insights, and information sourced from digital platforms, shifting consultations away from reactive care toward proactive health optimisation.
This shift is creating new complexity for physicians, who are being asked to engage with patients that are not traditionally “sick,” but are instead focused on prevention and long-term health outcomes. As a result, established healthcare models largely built around diagnosis and treatment are being challenged.
For life sciences companies, Ipsos suggests that traditional HCP engagement approaches may no longer be sufficient. The report highlights the need for education-led, multi-stakeholder engagement strategies, grounded in scientific credibility and adapted to varying healthcare system constraints.
Structural barriers remain a key consideration. Factors such as limited consultation time, reimbursement models, and gaps in clinical evidence are cited as constraints that can make longevity-focused conversations difficult to sustain in practice.
The report also notes the growing role of conferences, professional forums, and social media in shaping physician awareness and understanding of longevity medicine, pointing to an increasingly fragmented and digitally influenced information ecosystem.
solli’s Final Thoughts
The “longevity shift” represents more than a clinical evolution, it signals a media and communication shift.
As patients become more informed through digital channels and consumer health technologies, the traditional flow of information from pharma to physician to patient is becoming increasingly decentralised. For pharma media, this introduces a need to rethink where influence is built and how trust is earned.
